AcelRx Pharmaceuticals Reports Second Quarter 2018 Financial Results

Published: Aug 02, 2018

 

- European Commission approved DZUVEO (sufentanil sublingual tablet, 30 mcg) for the management of acute moderate-to-severe pain in adults in medically monitored settings
- June 30, 2018 cash and short-term investments balance of $50.1 million
- Combined R&D and G&A expenses declined 27% from H1 2017

REDWOOD CITY, Calif., Aug. 2, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today reported its second quarter 2018 financial results.

"The first half of the year has been productive on all fronts as we have accomplished all the milestones we established for the period. We're very focused on reaching our remaining milestones for the year and, if DSUVIA is approved in November, eager to start commercializing our first U.S. product in Q1 2019," said Vince Angotti, Chief Executive Officer of AcelRx. "We continue to believe we have a unique product for the management of moderate to severe acute pain that can fulfill an unmet need within appropriate healthcare settings. We look forward to continued dialogue with the FDA during the coming months to achieve these objectives," continued Angotti.

Recent Highlights

  • The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for DSUVIA in May.
  • Received approval from the European Commission for DZUVEO for the management of acute moderate-to-severe pain in medically monitored settings.
  • Completed an underwritten public offering of 7,272,727 shares of common stock, at a price of $2.75 per share to the public with estimated net proceeds to the company of $18.7 million.

Financial Information

  • June 30, 2018 cash and short-term investment balance of $50.1 million;
  • R&D and G&A expenses for the quarter ended June 30, 2018 totaled $7.2 million compared to $9.1 million for the prior year period. Excluding stock-based compensation expense, these figures were $6.2 million for the second quarter of 2018 compared to $8.1 million for the prior year period. R&D and G&A expenses for the first half of 2018 totaled $14.7 million compared to $20.1 million in the first half of 2017. Excluding stock-based compensation expense, these figures were $12.8 million for the first half of 2018 compared to $18.1 million for the prior year period. The decrease in R&D and G&A expenses in both periods is primarily due to lower Zalviso-related expenses attributed to the Phase 3 clinical program completed in 2017. See the "Reconciliation of Non-GAAP Financial Measures" table below for a reconciliation of the non-GAAP operating expenses described above to their related GAAP measures;
  • Net cash use during the second quarter 2018 was $8.5 million excluding proceeds from ATM facility, included $2.3 million of debt service; and
  • For the second quarter of 2018 net loss was $10.5 million, or $0.20 per basic and diluted share, compared to $13.1 million, or $0.29 per basic and diluted share, for the second quarter of 2017. Net loss for the first half of 2018 was $22.1 million, or $0.43 basic and diluted net loss per share, compared to $28.6 million, or $0.63 basic and diluted net loss per share, for the prior year period.

2018 Remaining Milestones

  • Expected FDA advisory committee meeting for DSUVIA in late Q3/early Q4 2018;
  • Prescription Drug User Fee Act, PDUFA, date for DSUVIA on November 3, 2018; and
  • Anticipated resubmission of NDA for Zalviso in Q4 2018.

Conference Call and Webcast Information
As previously announced, AcelRx will conduct an investment-community conference call today, August 2, 2018 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss these financial results and provide other corporate updates. Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers. Those interested in listening to a webcast of the conference call live via the Internet may do so by visiting the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page. The webcast will be archived on the AcelRx website for 90 days following the call.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has two product candidates including DSUVIA (sufentanil sublingual tablet, 30 mcg), known as DZUVEO outside the United States, with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, and Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.

For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Non-GAAP Financial Measures
To supplement AcelRx's financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP financial measures in this press release, in particular, excluding stock-based compensation expense from its operating expenses. The company believes that this non-GAAP financial measure provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that this non-GAAP financial measure, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance. In addition, this type of non-GAAP financial measure is regularly used by investors and analysts to model and track the company's financial performance. AcelRx's management also regularly uses this non-GAAP financial measure internally to understand, manage and evaluate the company's business and to make operating decisions. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with AcelRx's consolidated financial statements prepared in accordance with GAAP. The non-GAAP financial measures in this press release and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the process and timing of anticipated future development of AcelRx's product candidates, DSUVIA (sufentanil sublingual tablet, 30 mcg), known as DZUVEO outside the United States, and Zalviso® (sufentanil sublingual tablet system), including the anticipated resubmission of the Zalviso NDA, and the Company's anticipated conservation of cash in expectation of a potential commercial launch of DSUVIA, if approved. These forward-looking statements are based on AcelRx's current expectations and inherently involve significant risks and uncertainties. AcelRx's actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: any delays or inability to obtain and maintain regulatory approval of its product candidates, including DSUVIA and Zalviso in the United States; the possibility that the FDA may dispute or interpret differently the results of the company's Human Factors study to validate the effectiveness of the changes in the Directions for Use, or the supplemental information included in the resubmission of the NDA for DSUVIA; the possibility that the FDA may dispute or interpret differently the results of the Zalviso development program, including the results from the IAP312 clinical trial; the accuracy of AcelRx's estimates regarding expenses, capital requirements and the need for financing; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx's U.S. Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2018. AcelRx undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations, except as required by law.

                                                    Selected Financial Data

                                             (in thousands, except per share data)

                                                          (unaudited)


                                                    Three Months Ended                           Six Months Ended

                                                         June 30,                                    June 30,
                                                       --------                                 --------

                                                          2018                             2017                2018         2017
                                                          ----                             ----                ----         ----

    Statement of Comprehensive Loss Data


    Revenue:

    Collaboration agreement
     revenue                                              $351                           $2,192                $625       $5,219

    Contract and other
     revenue                                               467                              467                 536          549

          Total revenue                                    818                            2,659               1,161        5,768
                                                           ---                            -----               -----        -----


    Operating costs and expenses:

    Cost of goods sold (1)                                 749                            3,543               1,863        7,668

    Research and development
     (1)                                                3,278                            4,901               6,791       11,820

    General and
     administrative (1)                                  3,944                            4,156               7,929        8,294

    Total operating costs and
     expenses                                            7,971                           12,600              16,583       27,782
                                                         -----                           ------              ------       ------

    Loss from operations                               (7,153)                         (9,941)           (15,422)    (22,014)


    Other (expense) income:

    Interest expense                                     (586)                           (903)            (1,229)     (1,677)

    Interest income and other
     income (expense), net                                 195                              396                 331          250

    Non-cash interest
     expense on liability
     related to sale of
     future royalties                                  (2,995)                         (2,609)            (5,811)     (5,167)
                                                        ------                           ------              ------       ------

    Total other expense                                (3,386)                         (3,116)            (6,709)     (6,594)
                                                        ------                           ------              ------       ------

    Benefit (provision) for
     income taxes                                          (2)                             (2)                (2)         (2)

    Net loss                                         $(10,541)                       $(13,059)          $(22,133)   $(28,610)
                                                      ========                         ========            ========     ========


    Basic and diluted net
     loss per common share                             $(0.20)                         $(0.29)            $(0.43)     $(0.63)
                                                        ======                           ======              ======       ======


    Shares used in computing
     basic and diluted net
     loss per common share                              51,842                           45,379              51,389       45,364
                                                        ======                           ======              ======       ======





    (1)   Includes the following non-cash, stock-based compensation expense:


                Cost of goods sold                         $74                              $79                $161         $163

                Research and development                   377                              448                 809          985

                General and
                 administrative                            597                              551               1,158        1,074

                       Total                            $1,048                           $1,078              $2,128       $2,222
                                                        ======                           ======              ======       ======




                                                June 30, 2018               December 31, 2017
                                                -------------               -----------------

    Selected Balance Sheet Data

    Cash, cash equivalents
     and investments                                   $50,122                          $60,469

    Total assets                                        64,620                           75,552

    Total liabilities                                  113,586                          112,061

    Total stockholders'
     deficit                                          (48,966)                        (36,509)

 

    Reconciliation of Non-GAAP Financial Measures


    (Operating Expenses less associated stock-based compensation expense)


                                                          Three Months Ended        Six Months Ended

                                                               June 30,                 June 30,
                                                               --------                 --------

                                                             2018              2017               2018    2017
                                                             ----              ----               ----    ----


    Operating expenses (GAAP):

    Research and development                               $3,278            $4,901             $6,791 $11,820

    General and administrative                              3,944             4,156              7,929   8,294

    Total operating expenses                                7,222             9,057             14,720  20,114

    Less associated stock-based compensation expense

                                                              974               999              1,967   2,059

    Operating expenses (non-
     GAAP)                                                 $6,248            $8,058            $12,753 $18,055
                                                           ======            ======            ======= =======

 

 

View original content with multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-reports-second-quarter-2018-financial-results-300691401.html

SOURCE AcelRx Pharmaceuticals, Inc.

Company Codes: NASDAQ-NMS:ACRX

Back to news